Blue Jet Healthcare Ltd — Q3 FY26
Blue Jet Healthcare reported a sharp 40% YoY decline in Q3 FY26 revenue to ₹192.4 crore, with EBITDA down 62% and PAT down 39%, driven by destocking in the key pharma intermedia...
neutral
medium
Financial stats pending filing verification
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
33%Questions answered6Evaded / deflected12Questions auditedContradictedNumbers vs filing
Partial answer
High priority
When will destocking impact on pharma intermediate go away and outlook for FY27?
Asked by Amland Das, JP Morgan
Management gave a vague timeline of 'a couple of quarters' without specifics.
no specific timelinevague on recovery
Read the exchange
Question
when do you see this Dalking impact uh going away and and and how do you see this um year ending um especially on the fourth quarter?
Management (unidentified)
it might take a couple of quarters for this to get completely realigned. But if you would see that over the past 9 months also we have done significant volumes as far as our API uh vertical is concerned.
Partial answer
Medium priority
How many contrast media launches, revenue contribution, and market share?
Asked by Amland Das, JP Morgan
Management described launches but did not quantify revenue contribution or market share.
no revenue contribution numbersno market share data
Read the exchange
Question
how many launches have you done in this segment and how has it contributed to your revenue so far and which product has been a meaningful contributor?
Management (unidentified)
In contrast media there were uh two needle movers for us. One is an advanced intermediate for the existing product... The second molecule is the NC intermediate which has done well for us in the past 12 months.
Answered
Medium priority
How many late-stage API PI molecules and when will they contribute?
Asked by Amland Das, JP Morgan
Management gave a specific number (six) and a timeline (2 years).
Read the exchange
Question
how many molecules do you have in say the late stage or phase three assets uh in your PIP pipeline right now?
Management (unidentified)
The latest stage assets are about six and u um I think they'll start kicking in about 2 years from now.
Answered
High priority
What caused gross margin volatility? Inventory write-off details and product mix impact.
Asked by Sanjay Chain, ICICI Securities
Management quantified the inventory write-off impact at 1% and explained product mix effect.
Read the exchange
Question
can you give us more color on the inventory right down what and which product and how much did it hurt because the gross profit volatility has really been all over the place?
Ganesh (CFO)
gross margin on a YTD basis is around 53% compared to 54% 55% last financial year... 1% impact is roughly on some certain inventory writeups which are old stock... balance 1% is basically a swing off because of product mix.
Evasive
High priority
Where are we in supply chain realignment for bamboo acid? Will it benefit us?
Asked by Sanjay Chain, ICICI Securities
Management declined to provide details, calling it premature, but gave a vague positive assurance.
no specificsdeferred comment
Read the exchange
Question
where are we in that realignment? ... will it positively benefit us? Will it negatively benefit us?
Management (unidentified)
it's a little premature on our part to comment on it but all that I can say is that it'll work in our favor and it is not that supplies from blue jet are not going.
Partial answer
High priority
What gives confidence that FY27 will be better than FY26 in revenue growth and margins?
Asked by Sanjay Chain, ICICI Securities
Management cited capacity additions and customer orders but gave no specific revenue or margin targets.
no quantitative guidance
Read the exchange
Question
what gives us a confidence that FI27 should be better than FI 26 in terms of revenue growth and on the operating leverage helping to regain the margins.
Management (unidentified)
the two major lines that we had created one for the cardiovascular molecule and the other one was for the NC intermediate... both of them would be positively contributing for FI27 which is backed by some customer orders.
Evasive
Medium priority
What is the capex deployment schedule for FY27 given current volatility?
Asked by Shams Sat, MSA Capital Partners
Management deferred specific FY27 capex guidance to the next quarter.
deferred to next quarter
Read the exchange
Question
what will our capeex deployment schedule look like for the next FY27 uh given the current uh volatility that we have with Parma intermediates?
Management (unidentified)
we've committed a capeex of thousand crores over the next 3 to four years and specific targets for FI27 we'll give you in the next quarter.
Declined
High priority
What revenue threshold is needed to get back to 30%+ EBITDA margin?
Asked by Shams Sat, MSA Capital Partners
Management explicitly declined to provide any revenue threshold for margin recovery.
refused to guide
Read the exchange
Question
what kind of revenue threshold do we think we should expect to uh get back to the uh 30 plus margin mark.
Management (unidentified)
we cannot be uh unfortunately we cannot guide on those numbers now.
Evasive
High priority
How do contracts get renegotiated when a new supplier enters? Risk of volume loss?
Asked by Nikopadhya, SIMPL
Management did not explain how contracts are renegotiated or quantify potential volume impact.
no specifics on contract termsvague reassurance
Read the exchange
Question
when the renegotiation happens where a new supplier comes in. how does the business break up happen between the two suppliers?
Management (unidentified)
any new supplier entering has a regulatory pathway... we don't see those indicators at this point in time so we are still positive around this molecule.
Partial answer
High priority
Are the FY27 volumes for the PI molecule backed by firm orders?
Asked by Nikopadhya, SIMPL
Management confirmed binding forecasts and POs but refused to give specifics.
no specific numbers
Read the exchange
Question
are these firm orders which are signed or is it like it will be more closer to starting of financial year?
Management (unidentified)
there are binding forecasts and there are confirmed purchase orders but at this point in time it's very difficult to give specifics around that.
Evasive
Medium priority
When will contrast media see material double-digit growth?
Asked by Anish Burman, Varia
Management declined to provide an outlook for double-digit growth.
no timelineno growth guidance
Read the exchange
Question
when do we expect like a material double-digit growth here if if that is possible?
Management (unidentified)
terms of providing an outlook would be would be difficult but I think when I was trying to say that there are we'll scale up around three molecules.
Evasive
High priority
What is the normalized quarterly revenue for pharma intermediate?
Asked by Sujit Lora, ICICI Lombard
Management refused to provide normalized revenue numbers and suggested waiting.
no guidancedeferred to next quarter
Read the exchange
Question
what is the quarterly number one should work at for for fi 27 or one what is the annual number one should look at is 145 cr right number?
Management (unidentified)
we normally don't like to give a guidance like this... just wait for a quarter and then the run rate that you will see from that run rate you can extrapolate.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Gross margin YTD around 53% vs 54-55% last year | 53% | 20% | Overstated vs filing |
| Gross margin range 50-55% | 52.5% | 20% | Overstated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.